1. Home
  2. VUZI vs SLS Comparison

VUZI vs SLS Comparison

Compare VUZI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vuzix Corporation

VUZI

Vuzix Corporation

HOLD

Current Price

$3.51

Market Cap

246.0M

Sector

Technology

ML Signal

HOLD

Logo SELLAS Life Sciences Group Inc.

SLS

SELLAS Life Sciences Group Inc.

HOLD

Current Price

$4.07

Market Cap

208.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VUZI
SLS
Founded
1997
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.0M
208.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VUZI
SLS
Price
$3.51
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
3.1M
11.1M
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,310,001.00
N/A
Revenue This Year
$5.53
N/A
Revenue Next Year
$110.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$0.85
52 Week High
$5.79
$5.18

Technical Indicators

Market Signals
Indicator
VUZI
SLS
Relative Strength Index (RSI) 57.33 69.48
Support Level $3.15 $2.60
Resistance Level $4.04 $5.18
Average True Range (ATR) 0.35 0.49
MACD 0.05 0.20
Stochastic Oscillator 63.87 65.63

Price Performance

Historical Comparison
VUZI
SLS

About VUZI Vuzix Corporation

Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Share on Social Networks: